Our Sectors
We are experts at what we do
01
Our People
A dedicated team of executive search experts, delivering for you
The Compass Carter Osborne team are healthcare and life science experts. As a trusted advisor we bring decades of search experience and an unparalleled track record of delivery across our dedicated sectors for our investor clients – relied upon time and again to build outstanding leadership teams.
Familiar faces at key industry events, our expertise extends beyond the mere placing of people with our consultants bringing together sector leaders to address key challenges, working in partnership to produce tangible solutions.
02
Expertise
Unearthing rare talent, that drive successful exits
Responsive, adaptable, and emotionally intelligent, Compass Carter Osborne avoid the one-size-fits-all approach to ensure our clients achieve their desired outcome by presenting a broad range of intuitive, tailored solutions, based on specific needs.
03
Our Approach
Tailoring our offering,
to provide a bespoke service
Results driven, not process led, CCO avoid the conformity of a rigid process. Never assumptive, we listen and adopt an agreed approach which most closely delivers to a clients specific needs. Understanding the uniqueness of each role, our people tailor a search to bespoke requirements to ensure solutions that delivers the best possible results first time, every time.
A trusted advisor to the investment community
providing leaders advancing the healthcare and life sciences sectors
What our clients say
“Compass Carter Osborne really delivered for us in our search for a new CEO for Outcomes First Group. It was a vitally important assignment given that we were recruiting a successor for a long standing and highly successful CEO in a sector-leading business. Compass Carter Osborne went above and beyond in developing a deep understanding of the business and our requirements, and in only presenting candidates that closely met these. They think very creatively and their focus was very sharp; they particularly understood the culture of the business. The search was speedy and well organised, with a very high standard of verbal and written feedback. They have a granular knowledge of the sector and because of the way in which they work, we were fully involved throughout and achieved a great result. A really excellent search – thank you.”
Outcomes First Group – Chair
“Compass Carter Osborne started from the very beginning with a detailed, professional explanation of the available position. They spent time to present the great opportunity and chance to accelerate my career but at the same time, the challenge, and the strong expectation from their client.”
Hengrui Therapeutics – VP, Head Biological Drug Discovery
“Compass Carter Osborne delivered on a key appointment for the PFA and the wider football industry. It was a complex brief involving creating an entirely new position. The role was vitally important, with the successful candidate taking on a sensitive and multifaceted responsibility across CTE, concussion and brain health in professional football. CCO led a comprehensive and exhaustive process, developing a deep understanding of the union’s requirements and using his expert knowledge to help scope and evolve the brief throughout the search. The entire process was professional, efficient and well organised, with consistent communication and feedback at every stage.”
The Professional Footballers Association (PFA) – Chief Executive Officer
“I have been so impressed by Luke’s integrity, clear purpose and drive to achieve for his clients. Luke has worked with Priory on a number of things but more recently to source two independent Non Executive Directors and a Director of Talent Acquisition. He has kept us informed, fielded some great candidates and follows up at each stage, even when they have started. I would really recommend him if you are searching for high calibre individuals.”
Priory Group – Chief Executive Officer
“I recently had the pleasure of being appointed to an independent healthcare provider as a NED after being put forward for the role by Luke. Throughout the whole recruitment process I was treated with respect and felt valued. I was particularly impressed with the follow up support after the decision to appoint me, which I have never experienced from other search companies. Luke continued to check in with me to ensure my onboarding went smoothly and that I had settled into the role. Overall, a highly professional and comprehensive approach delivered personally by Luke.”
Priory – Independent Non-Executive Director
“Luke was absolutely brilliant along the journey. He acted as a real partner and was able to answer to all my questions in order to get comfortable with the decision of making the change. His expertise and knowledge of the sector really came out along the process. Most importantly, he was always available when I needed him to be, which is something I valued a lot. In summary, I couldn’t recommend him and Compass Carter Osborne enough.”
AniCura – Group Chief Operating Officer
“We worked with Compass Carter Osborne in the search for our Chief Financial Officer and from the start it was clear they were a good choice of partner. A focus on understanding our needs as a business, and mine personally as a CEO were front of mind for Paul and Kieran. They took the time to listen, understand and not only focus on the functional aspects of the role – but critically, the team fit and culture we are building.
Process, structure and follow-through were like clockwork, and the quality of candidates were of a consistently high-level. I would highly recommend Compass Carter Osborne.”
Renaiss Health – Chief Executive Officer
“I’ve known Tarquin for over 15 years, during which time he has delivered a number of executive assignments at senior level, including COO/executive team and senior management roles in scientific/professional disciplines (his network in the biotech/life-sciences sector is second-to-none!). He works hard to truly understand both the candidate brief and the culture of the company, sets realistic expectations and retains regular contact as an assignment progresses, always providing thorough updates and pragmatic advice. He has the highest levels of professionalism and integrity – he really is a pleasure to work with.”
One Nucleus – Director
“Jamie did a great job – he really took the time to understand our business, our needs and what we were looking for. We knew our brief was specific, yet Jamie met all our expectations with the search. He maintained a high standard of communication and meticulous attention to detail throughout the process. I would recommend Jamie and the Compass Carter Osborne team without hesitation.”
Melrose Education – Chair & CEO
“Our recent work with Compass Carter Osborne was exceptional. The search was perfectly organised, response times were swift, and due to the consultant market knowledge and network, we quickly found our ideal candidate.”
Schoen Clinic – Member of Group Executive
Healthcare news, data and analysis
Via Investors in Healthcare
Spain: Columna Capital acquires majority stake in Evidenze Group from Buenavista Equity Partners
Columna Capital has acquired a majority stake in Evidenze Group, a Spain‑based full‑service CRO, from Buenavista Equity Partners. The UK‑based pan‑European lower mid‑market investor is partnering with Evidenze co‑founders Pedro […]
Columna Capital has acquired a majority stake in Evidenze Group, a Spain‑based full‑service CRO, from Buenavista Equity Partners. The UK‑based pan‑European lower mid‑market investor is partnering with Evidenze co‑founders Pedro […]
Spain: Columna Capital acquires majority stake in Evidenze Group from Buenavista Equity Partners
May 5, 2026
Buy Out
M&A
News
Pharma
Services – CRO/CMO/CDMO
France: Jeito bolsters leadership team with Elaine Caughey and Sarah Shakleton
Jeito Capital, a France-based global independent private equity fund dedicated to Biopharma, has appointed Elaine Caughey as partner, business development and investor relations, and Sarah Shackelton as partner, talent. With […]
Jeito Capital, a France-based global independent private equity fund dedicated to Biopharma, has appointed Elaine Caughey as partner, business development and investor relations, and Sarah Shackelton as partner, talent. With […]
France: Jeito bolsters leadership team with Elaine Caughey and Sarah Shakleton
May 5, 2026
News
People
Pharma
Elaine Caughey
France
UK: Atlas Health holds final close of debut Atlas Health Fund I at £400m hard cap
Atlas Health, a private equity fund established to invest in European Healthcare companies, has held an oversubscribed final close of its debut fund, Atlas Health Fund I, at its £400m […]
Atlas Health, a private equity fund established to invest in European Healthcare companies, has held an oversubscribed final close of its debut fund, Atlas Health Fund I, at its £400m […]
UK: Atlas Health holds final close of debut Atlas Health Fund I at £400m hard cap
May 5, 2026
Animal Health
Life Sciences
Manufacturing – Specialty Pharma
Medtech – Diagnostics
Medtech – Healthcare IT
Sweden: Medicover signs €450m syndicated revolving credit facility
Stockholm-listed, Sweden-based international healthcare and diagnostic services company, Medicover, has signed a new €450m (US$526m) syndicated revolving credit facility agreement. The new facility replaces the existing €300m revolving credit facility […]
Stockholm-listed, Sweden-based international healthcare and diagnostic services company, Medicover, has signed a new €450m (US$526m) syndicated revolving credit facility agreement. The new facility replaces the existing €300m revolving credit facility […]
Sweden: Medicover signs €450m syndicated revolving credit facility
May 5, 2026
Debt
Diagnostics
Healthcare
News
Bank Pekao
Belgium: UCB expanding capabilities in next‑generation biologics with acquisition of Candid Therapeutics
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, is to acquire Candid Therapeutics, a US-based privately held clinical-stage biotechnology company redefining the treatment of autoimmune […]
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, is to acquire Candid Therapeutics, a US-based privately held clinical-stage biotechnology company redefining the treatment of autoimmune […]
Belgium: UCB expanding capabilities in next‑generation biologics with acquisition of Candid Therapeutics
May 5, 2026
M&A
Manufacturing – Specialty Pharma
News
Pharma
Belgium
A healthcare investor’s guide to “AI exposure”
Artificial intelligence is already reshaping workflows and productivity across all industries. The implications for value creation, however, are far from uniform. Filippos Papadopoulos, senior analyst, Seren Marsh, clinical fellow, and […]
Artificial intelligence is already reshaping workflows and productivity across all industries. The implications for value creation, however, are far from uniform. Filippos Papadopoulos, senior analyst, Seren Marsh, clinical fellow, and […]
A healthcare investor’s guide to “AI exposure”
May 5, 2026
Analysis
Healthcare
Life Sciences
News
Pharma
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights business of IMIDomics, a US-based biotechnology company focused on drug discovery […]
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights business of IMIDomics, a US-based biotechnology company focused on drug discovery […]
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business
May 1, 2026
M&A
Manufacturing – Specialty Pharma
News
Pharma
Alistair Henry
UK: Lazard acquisition of Campbell Lutyens to create leading global Private Capital Advisory
New York-listed Lazard, a global financial advisory and asset management firm, is acquiring Campbell Lutyens, a UK-based global private markets advisor focused on fund placement, secondary advisory, and GP capital […]
New York-listed Lazard, a global financial advisory and asset management firm, is acquiring Campbell Lutyens, a UK-based global private markets advisor focused on fund placement, secondary advisory, and GP capital […]
UK: Lazard acquisition of Campbell Lutyens to create leading global Private Capital Advisory
May 1, 2026
M&A
News
Campbell Lutyens
Gordon Bajnai
Holcombe Green
Germany: Greenpeak-backed athagoras adds Ecker + Ecker and Accessus Health to growing network of consultants
Greenpeak Partners‑backed athagoras, a Germany‑based platform of life sciences consultants, has added Ecker + Ecker and Accessus Health to the group, representing a clear move toward a leading position in […]
Greenpeak Partners‑backed athagoras, a Germany‑based platform of life sciences consultants, has added Ecker + Ecker and Accessus Health to the group, representing a clear move toward a leading position in […]
Germany: Greenpeak-backed athagoras adds Ecker + Ecker and Accessus Health to growing network of consultants
May 1, 2026
Buy Out
M&A
News
Pharma
Services – Medical Communications
Germany: Demetra strengthens its position in spine surgery with acquisition of Maxxspine Innovative
Demetra, an Italy-based independent medical company providing anti-infective cements, spacers and biomaterials for orthopaedic applications, has acquired Maxxspine Innovative, a German-based company specialising in advanced spinal surgery solutions. The transaction strengthens […]
Demetra, an Italy-based independent medical company providing anti-infective cements, spacers and biomaterials for orthopaedic applications, has acquired Maxxspine Innovative, a German-based company specialising in advanced spinal surgery solutions. The transaction strengthens […]
Germany: Demetra strengthens its position in spine surgery with acquisition of Maxxspine Innovative
April 30, 2026
Life Sciences
M&A
Medtech – Medical Devices and Implants
News
Demetra
Italy: Chiesi Group expanding global Rare Disease portfolio with US$1.9bn acquisition of KalVista
Chiesi Group, an Italy-based, family-controlled, international research-focused biopharmaceutical group and certified B Corp, is acquiring Nasdaq-listed KalVista Pharmaceuticals, a global pharmaceutical company focused on addressing the critical unmet needs of […]
Chiesi Group, an Italy-based, family-controlled, international research-focused biopharmaceutical group and certified B Corp, is acquiring Nasdaq-listed KalVista Pharmaceuticals, a global pharmaceutical company focused on addressing the critical unmet needs of […]
Italy: Chiesi Group expanding global Rare Disease portfolio with US$1.9bn acquisition of KalVista
April 30, 2026
M&A
Manufacturing – Specialty Pharma
News
Pharma
Ben Palleiko
France: Stago accelerating growth with Archimed and La Caisse
Archimed Diagnostics – the diagnostics team of France‑based global healthcare private equity specialist Archimed – has acquired Stago, a world leader in haemostasis analysis. Stago, headquartered in France, develops and […]
Archimed Diagnostics – the diagnostics team of France‑based global healthcare private equity specialist Archimed – has acquired Stago, a world leader in haemostasis analysis. Stago, headquartered in France, develops and […]
France: Stago accelerating growth with Archimed and La Caisse
April 29, 2026
Buy Out
IVD – Tools
Life Sciences
M&A
Medtech – Diagnostics
Iceland: NIB finances nursing home and healthcare facilities in Reykjavik
NIB, the international financial institution of Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, and Sweden, has signed an ISK4.4bn (US$36m) 10-year indexed loan with the listed Icelandic real estate company Reitir hf. The loan will […]
NIB, the international financial institution of Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, and Sweden, has signed an ISK4.4bn (US$36m) 10-year indexed loan with the listed Icelandic real estate company Reitir hf. The loan will […]
Iceland: NIB finances nursing home and healthcare facilities in Reykjavik
April 29, 2026
Care Homes
Debt
Healthcare
Hospitals and Clinics
News
Switzerland: vVardis reaches unicorn status following investment from Apollo
vVardis Holding, a Switzerland-based dental medtech company pioneering non-invasive cavity treatment, has achieved unicorn status following a strategic minority investment from US-based Apollo-managed funds. The investment establishes vVardis as one […]
vVardis Holding, a Switzerland-based dental medtech company pioneering non-invasive cavity treatment, has achieved unicorn status following a strategic minority investment from US-based Apollo-managed funds. The investment establishes vVardis as one […]
Switzerland: vVardis reaches unicorn status following investment from Apollo
April 29, 2026
Dental
Healthcare
News
Venture
Andrea Vanni
France: Echosens appoints Romain Baujard as group CEO
Echosens, a France-based specialist diagnostic company providing non-invasive medical devices and services to support physicians in their diagnostic and monitoring of chronic liver diseases, has appointed Romain Baujard as group […]
Echosens, a France-based specialist diagnostic company providing non-invasive medical devices and services to support physicians in their diagnostic and monitoring of chronic liver diseases, has appointed Romain Baujard as group […]
France: Echosens appoints Romain Baujard as group CEO
April 28, 2026
Diagnostics
Healthcare
News
People
Astorg
Namibia: Salt Capital and Proparco acquire The Namibian Oncology Centre
Salt Capital, a private equity investment firm focused on growth capital investments in the SADC region, and Proparco, the French Development finance institution, have acquired The Namibian Oncology Centre (NOC), […]
Salt Capital, a private equity investment firm focused on growth capital investments in the SADC region, and Proparco, the French Development finance institution, have acquired The Namibian Oncology Centre (NOC), […]
Namibia: Salt Capital and Proparco acquire The Namibian Oncology Centre
April 28, 2026
Buy Out
Healthcare
Hospitals and Clinics
M&A
M&A Deals
UK: Allica Bank expands lending and products in support of healthcare businesses
UK-based business challenger bank, Allica Bank, is announced it is expanding its lending and product flexibility in support of UK healthcare operators. The changes enable the bank to better support […]
UK-based business challenger bank, Allica Bank, is announced it is expanding its lending and product flexibility in support of UK healthcare operators. The changes enable the bank to better support […]
UK: Allica Bank expands lending and products in support of healthcare businesses
April 28, 2026
Debt
Healthcare
News
Allica Bank
Anthony Newman
Luxembourg: Astorg to acquire Thermo Fisher Scientific’s microbiology business for US$1.075bn
Astorg, a pan European private equity firm, has signed a definitive agreement to acquire New York-listed Thermo Fisher Scientific’s microbiology business for approximately US$1.075bn, consisting of cash and a US$50m […]
Astorg, a pan European private equity firm, has signed a definitive agreement to acquire New York-listed Thermo Fisher Scientific’s microbiology business for approximately US$1.075bn, consisting of cash and a US$50m […]
Luxembourg: Astorg to acquire Thermo Fisher Scientific’s microbiology business for US$1.075bn
April 27, 2026
Buy Out
Life Sciences
M&A
Medtech – Diagnostics
News
France: Servier acquires Day One Bio for US$2.5bn
France-headquartered Servier, an independent international pharmaceutical group governed by a foundation, has acquired Nasdaq-listed Day One Biopharmaceuticals, a biopharmaceutical company developing and commercialising targeted therapies for people of all ages […]
France-headquartered Servier, an independent international pharmaceutical group governed by a foundation, has acquired Nasdaq-listed Day One Biopharmaceuticals, a biopharmaceutical company developing and commercialising targeted therapies for people of all ages […]
France: Servier acquires Day One Bio for US$2.5bn
April 27, 2026
M&A
Manufacturing – Specialty Pharma
News
Pharma
Day One Bio
Netherlands: Waterland raises €4.6bn in less than four months
Netherlands-based independent PE investment group, Waterland, has announced the closing of its 10th institutional flagship fund Waterland Private Equity Fund X (WPEF X) at €4bn (US$4.7bn), alongside Waterland Partnership Fund II […]
Netherlands-based independent PE investment group, Waterland, has announced the closing of its 10th institutional flagship fund Waterland Private Equity Fund X (WPEF X) at €4bn (US$4.7bn), alongside Waterland Partnership Fund II […]
Netherlands: Waterland raises €4.6bn in less than four months
April 27, 2026
Buy Out
Healthcare
News
Cedric Van Cauwenberghe
Evercore
Hungary: LDC-backed Panthera Biopartners takes first major step in European expansion strategy
Panthera Biopartners (Panthera), the LDC-backed UK based clinical trial Site Management Organisation (SMO), has announced the acquisition of Óbudai Egészségügyi Centrum Kft (OEC), a Hungary-based independent clinical research site network. […]
Panthera Biopartners (Panthera), the LDC-backed UK based clinical trial Site Management Organisation (SMO), has announced the acquisition of Óbudai Egészségügyi Centrum Kft (OEC), a Hungary-based independent clinical research site network. […]
Hungary: LDC-backed Panthera Biopartners takes first major step in European expansion strategy
April 27, 2026
Buy Out
M&A
News
Pharma
Services – CRO/CMO/CDMO
Switzerland: Partners Group closes latest private equity secondaries programme with over US$9bn of total commitments
Partners Group, one of the largest firms in the global private markets industry, has closed its eighth private equity secondaries programme with over US$9bn in total client commitments. The programme […]
Partners Group, one of the largest firms in the global private markets industry, has closed its eighth private equity secondaries programme with over US$9bn in total client commitments. The programme […]
Switzerland: Partners Group closes latest private equity secondaries programme with over US$9bn of total commitments
April 24, 2026
Buy Out
News
Anthony Shontz
Partners Group
Switzerland
Sweden: Northern Horizon announces second fund raise in Q1 2026
Northern Horizon, the leading specialised social infrastructure investment manager in the Nordics, closed the first quarter of 2026 with another funding round of approximately €100m (US$117m) for its flagship evergreen […]
Northern Horizon, the leading specialised social infrastructure investment manager in the Nordics, closed the first quarter of 2026 with another funding round of approximately €100m (US$117m) for its flagship evergreen […]
Sweden: Northern Horizon announces second fund raise in Q1 2026
April 24, 2026
Care Homes
News
Real Assets
Social Care
Christoffer Abramson
Netherlands: Alcami to acquire contract packaging organisation Tjoapack
Alcami Corporation, a US-based CDMO, is acquiring Tjoapack, a Netherlands-based global contract packaging organisation (CPO) serving the pharmaceutical and biotech industries. Ampersand Capital Partners acquired a majority stake in Tjoapack […]
Alcami Corporation, a US-based CDMO, is acquiring Tjoapack, a Netherlands-based global contract packaging organisation (CPO) serving the pharmaceutical and biotech industries. Ampersand Capital Partners acquired a majority stake in Tjoapack […]
Netherlands: Alcami to acquire contract packaging organisation Tjoapack
April 24, 2026
Buy Out
M&A
News
Pharma
Services – CRO/CMO/CDMO
France: Kurma Partners closes Biofund IV at €215m
Kurma Partners, a European healthcare venture capital firm and a Eurazeo group company, has announced the final closing of Biofund IV at €215m (US$252m), some 35% larger than its previous […]
Kurma Partners, a European healthcare venture capital firm and a Eurazeo group company, has announced the final closing of Biofund IV at €215m (US$252m), some 35% larger than its previous […]
France: Kurma Partners closes Biofund IV at €215m
April 23, 2026
Healthcare
Life Sciences
News
Pharma
Venture
The latest insights from
Compass Carter Osborne
Insights from the Investors in Healthcare Real Assets Conference
Insights from the Investors in Healthcare Real Assets Conference
February 9, 2026
Healthcare
Insight
Digital transformation or change fatigue? Navigating tech in health and care
Digital transformation or change fatigue? Navigating tech in health and care
November 24, 2025
Healthcare
Insight